RecruitingNCT06386094

Cardiac Dysfunction in Patients with Fatty Liver Disease

Cirrhotic Cardiomyopathy and Cardiac Dysfunction in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease


Sponsor

Post Graduate Institute of Medical Education and Research, Chandigarh

Enrollment

150 participants

Start Date

Jul 15, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how fatty liver disease (known as metabolic dysfunction-associated steatotic liver disease, or MASLD) affects the heart. Researchers want to understand the relationship between liver fat buildup and cardiac dysfunction using heart and liver imaging. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with fatty liver disease (MASLD) based on imaging, lab tests, or liver biopsy **You may NOT be eligible if...** - You are older than 65 - You have chronic kidney disease - You are pregnant or have peripartum cardiomyopathy (heart weakness after childbirth) - You have high blood pressure, heart valve disease, or a pacemaker - You have thyroid problems - You have liver cancer - You are severely anemic Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEchocardiographic assessment

M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.


Locations(1)

Dr. Madhumita Premkumar

Chandigarh, Chandigarh, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06386094


Related Trials